Feuchtenberger, Martin http://orcid.org/0000-0001-8028-8099
Kovacs, Magdolna Szilvia http://orcid.org/0000-0001-9215-6501
Eder, Anna http://orcid.org/0000-0002-6154-4322
Nigg, Axel http://orcid.org/0000-0001-5805-806X
Schäfer, Arne http://orcid.org/0000-0001-6600-3691
Article History
Received: 18 February 2022
Accepted: 20 March 2022
First Online: 16 April 2022
Declarations
:
: Dr. Feuchtenberger reports personal fees from AbbVie, personal fees from Roche, and personal fees from UCB outside of the submitted work. Dr. Kovacs has nothing to disclose. Dr. Eder has nothing to disclose. Dr. Nigg has nothing to disclose. Dr. Schäfer reports personal fees from Amgen, AstraZeneca, Novo Nordisk Pharma GmbH, outside the submitted work.
: The study was approved by the ethics committee of the University of Würzburg, Germany, on 13 July 2021 (207/21-me).
: All patients provided written informed consent for blood analysis, study participation and publication of data.